α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives
OM Alzghool, G van Dongen… - Movement …, 2022 - Wiley Online Library
ABSTRACT α‐Synucleinopathies including idiopathic Parkinson's disease, dementia with
Lewy bodies and multiple systems atrophy share overlap** symptoms and pathological …
Lewy bodies and multiple systems atrophy share overlap** symptoms and pathological …
State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET
M Chomet, GAMS van Dongen… - Bioconjugate chemistry, 2021 - ACS Publications
Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or
antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is …
antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is …
PET‐CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients
IHC Miedema, GJC Zwezerijnen… - Advanced …, 2022 - Wiley Online Library
Several FDA/EMA‐approved nanomedicines have demonstrated improved
pharmacokinetics and toxicity profiles compared to their conventional chemotherapeutic …
pharmacokinetics and toxicity profiles compared to their conventional chemotherapeutic …
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
IHC Miedema, MC Huisman, GJC Zwezerijnen… - European journal of …, 2023 - Springer
Purpose Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate
promising clinical anti-cancer activity, only a subset of patients seems to benefit and …
promising clinical anti-cancer activity, only a subset of patients seems to benefit and …
Targeted nuclear medicine. Seek and destroy
VM Tolmachev, VI Chernov… - Russian Chemical …, 2022 - iopscience.iop.org
The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …
treatment of malignant neoplasms. The development of scaffold proteins has significantly …
Long versus short axial field of view immuno-PET/CT: semiquantitative evaluation for 89Zr-trastuzumab
P Mohr, J van Sluis, L Providência… - Journal of nuclear …, 2023 - Soc Nuclear Med
The purpose of this study was to quantify any differences between the SUVs of 89Zr immuno-
PET scans obtained using a PET/CT system with a long axial field of view (LAFOV; Biograph …
PET scans obtained using a PET/CT system with a long axial field of view (LAFOV; Biograph …
Zirconium immune-complexes for PET molecular imaging: current status and prospects
L Melendez-Alafort, G Ferro-Flores, L De Nardo… - Coordination Chemistry …, 2023 - Elsevier
Diagnostic molecular images, obtained by positron emission tomography (PET), have
successfully functioned as sensitive tools for detecting and monitoring the treatment of …
successfully functioned as sensitive tools for detecting and monitoring the treatment of …
Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
N Stergiou, TE Wuensche, M Schreurs, I Mes… - European journal of …, 2023 - Springer
Purpose The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer's
disease (AD) and the continued discussions around that decision have increased interest in …
disease (AD) and the continued discussions around that decision have increased interest in …
PD-L1 peptides in cancer immunoimaging and immunotherapy
S Du, J Liu, Y Zhang, X Ge, S Gao, J Song - Journal of Controlled Release, 2025 - Elsevier
The interaction between programmed death protein 1 (PD-1) and programmed death ligand
1 (PD-L1) constitutes a critical immune checkpoint pathway that leads to immune tolerance …
1 (PD-L1) constitutes a critical immune checkpoint pathway that leads to immune tolerance …
[HTML][HTML] Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody-The choice of chelator is essential
TE Wuensche, N Stergiou, I Mes, M Verlaan… - Theranostics, 2022 - ncbi.nlm.nih.gov
The accelerated approval of the monoclonal antibody (mAb) aducanumab as a treatment
option for Alzheimer's Disease and the continued discussions about its efficacy have shown …
option for Alzheimer's Disease and the continued discussions about its efficacy have shown …